Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

1995 ◽  
Vol 120 (2) ◽  
pp. 128-133 ◽  
Author(s):  
D. C. Hoffman ◽  
H. Donovan
Keyword(s):  
Side Effect ◽  
Antipsychotic Drugs ◽  
Rodent Model ◽  
Extrapyramidal Side Effect

scholarly journals EVALUATION OF THE EXTRAPYRAMIDAL SIDE- EFFECT LIABILITY OF PEROSPIRONE (SM-9018), A NOVEL ANTIPSYCHOTIC DRUG, BY THE RAT PAW TEST

1996 ◽  
Vol 71 ◽  
pp. 184
Author(s):  
Hideki Sakamoto ◽  
Yukihiro Ohno ◽  
Tomoko Morita ◽  
Kenji Matsumoto ◽  
Mitsutaka Nakamura
Keyword(s):  
Antipsychotic Drug ◽  
Side Effect ◽  
Extrapyramidal Side Effect ◽  
Rat Paw ◽  
Novel Antipsychotic

scholarly journals A case of clarithromycin psychosis

2004 ◽  
Vol 28 (3) ◽  
pp. 98-99 ◽  
Author(s):  
Fawad Elahi ◽  
Moosajee Bhamjee
Keyword(s):  
Atypical Antipsychotic ◽  
Intravenous Administration ◽  
Side Effect ◽  
Antipsychotic Drugs ◽  
Psychiatric Hospitalisation ◽  
Atypical Antipsychotic Drugs ◽  
Psychotic Reaction ◽  
Rare Side Effect

A 19-year-old woman developed an immediate psychotic reaction following intravenous administration of clarithromycin. She responded to atypical antipsychotic drugs but needed psychiatric hospitalisation. She recovered after a year and is now symptom-free without any medication. This is a rare side-effect, but needs to be recognised.

scholarly journals Examining side effect variation of antipsychotic treatment in schizophrenia spectrum disorders

2020 ◽  
Author(s):  
Maria S. Neumeier ◽  
Stephanie Homan ◽  
Stefan Vetter ◽  
Erich Seifritz ◽  
John M. Kane ◽  
...  
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Precision Medicine ◽  
Side Effect ◽  
Antipsychotic Drugs ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Second Generation Antipsychotics ◽  
Spectrum Disorders ◽  
The Right

Background: Side effects of antipsychotic drugs play a key role in non-adherence and discontinuation of treatment in schizophrenia spectrum disorders (SSD). Precision medicine aims to minimize such side effects by selecting the right treatment for the right patient. However, to determine the extent of precision medicine that is required, we need to (1) show that there is indeed variation in side effects and (2) estimate the amount of variation in those side effects between patients. While clinical observations suggest that such variation may be considerable, a statistical comparison of side effect variation between active and control treatments is required to confirm this. Here, we hypothesized to find larger side effect variation in treatment compared with control in patients treated with first and second generation antipsychotics. Methods: We included double-blind, placebo-controlled, randomized controlled trials (RCTs) of adults with a diagnosis of SSD and prescription for licensed antipsychotic drugs. Standard deviations of the pre-post treatment differences of weight gain, prolactin levels,and corrected QT (QTc) times were extracted. Data quality and validity were ensured by following the PRISMA guidelines. The outcome measure was the overall variability ratio of treatment to control across RCTs. Individual variability ratios were weighted by the inverse-variance method and entered into a random-effects model. Results: We included N = 16578 patients for weight gain, N = 16633 patients for prolactin levels, and N = 10384 patients for QTc time. Variability ratios (VR) were significantly increased for weight gain (VR = 1.08; 95% CI: 1.02 - 1.14; P = 0.004) and prolactin levels (VR = 1.38; 95% CI: 1.17 - 1.62; P < 0.001) but did not reach significance for QTc time (VR = 1.05; 95% CI: 0.98 - 1.12; P = 0.135). Conclusion: We found increased variability in major side effects in patients with SSD under treatment with second generation antipsychotics, suggesting that subgroups of patients or even individual patients may benefit from improved treatment allocation through stratified or personalized medicine, respectively.

Towards More Effective Antipsychotic Treatment

1994 ◽  
Vol 165 (S25) ◽  
pp. 22-31 ◽  
Author(s):  
John M. Kane ◽  
Hugh L. Freeman
Keyword(s):  
Side Effect ◽  
Negative Symptoms ◽  
Antipsychotic Drugs ◽  
Mechanisms Of Action ◽  
Effective Control ◽  
Antipsychotic Treatment ◽  
Side Effect Profile ◽  
Proven Efficacy ◽  
Dopamine Hypothesis ◽  
Neurological Effects

The development of antipsychotic drugs has followed two complementary approaches, either towards highly specific actions (e.g. on the dopamine receptor) or targeting a broad range of receptors. The properties of ‘atypical’ agents challenge the original dopamine hypothesis and suggest roles for a variety of dopamine receptors and for other pathways, such as serotonin. Older drugs, despite their proven efficacy in relieving many schizophrenic symptoms, have several drawbacks, being ineffective in some patients, relatively ineffective against negative symptoms, and causing adverse neurological effects which may, in turn, be associated with poor compliance. Among newer agents, currently available ones, such as clozapine and risperidone, offer the possibility of more effective control of negative symptoms and an improved side-effect profile, while others are in earlier stages of development. However, much still remains to be understood about their mechanisms of action.

Sign in / Sign up

Export Citation Format

Share Document